AdvaMed To Seek Legislative Fix To Ease New Tech Add-On Payment Criteria
This article was originally published in The Gray Sheet
Executive Summary
CMS' discovery that Stryker Biotech (OP-1) has offered a comparable product to Medtronic's InFuse bone graft for tibia fractures since 2001 led the agency to reject the latter firm's new technology add-on application